Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: Further outcome for patients event-free survivors 5 years from the beginning of treatment

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 2037-2040

  Bacci, Gaetano ^a   Balladelli, A ^a   Forni, C ^a   Ferrari, S ^a   Longhi, A ^a   Benassi, M S ^a   Briccoli, A ^a   Serra, M ^a   Picci, P ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Adriamycin cardiopathy; Ewing's sarcoma; Late events; Osteosarcoma; Radio induced sarcoma; Second malignancy

Indexed keywords

DOXORUBICIN;

ADJUVANT THERAPY; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOMYOPATHY; CAUSE OF DEATH; CONTROLLED STUDY; EWING SARCOMA; FAMILIAL CANCER; HUMAN; LEUKEMIA; LUNG METASTASIS; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; SARCOMA; SECOND CANCER; SOLID TUMOR; SUICIDE; SURVIVAL TIME; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EXTREMITIES; HUMANS; OSTEOSARCOMA; SARCOMA, EWING'S; TREATMENT OUTCOME;

EID: 37349060107     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm382     Document Type: Article

References (26)

1. Bernstein M, Kovar H, Paulussen M et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006; 11: 503-519.
2. Whelan J, Seddon B, Perlsoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006; 7: 444-455.
3. Bacci G, Ruggieri P, Picci P et al. Changing pattern of relapse in osteosarcoma of the extremities treated with ajuvant and neoadjuvant chemotherapy. J Chernother 1995; 7: 230-239.
4. Bacci G, Longhi A, Ferrari S et al. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotheraphy between 1972 and 1999. Eur J Surg Oncol 2006; 32: 974-979.
5. Chi SN, Conklin LS, Qin J et al. The patterns of relapse in osteosarcolna: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004; 42: 46-51.
6. Goorin AM, Shuster JL Baker A et al. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Onool 1991; 9: 600-605.
7. Pratt CB, Meyer WH, Luo X et al. Second malignant neoplasms occuring in survivors of osteosarcoma. Cancer 1997; 80: 960-965.
8. Aung L, Gorlick RG, Shi W et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience Cancer 2002; 95: 1728-1734.
9. Goorin AM, Chauvenet AR, Perez-Atayde AR et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144-147.
10. Bacci G, Longhi A, Fagioli F et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 2005; 41: 2836-2845.
11. Bacci G, Longhi A, Ferrari S et al. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006; 45: 469-475.
12. Falk S, Alpert M. Five-year survival of patients with Ewing's sarcoma. Surg Gynecol Obstet 1967; 124: 319-324.
13. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy an relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606.
14. Longhi A, Errani C, De Paolis M et al. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006; 32: 423-436.
15. Grier HE, Krallo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
16. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818-1829.
17. Nesbit ME Jr. Gehan EA, Burgert EO Jr et al. Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8: 1664-1674.
18. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term-results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997; 33: 1061-1069.
19. Kinsella TJ, Miser JS, Waller B el al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Onool Biol Phys 1991; 20: 389-395.
20. Weston CL, Douglas C, Craft AW et al. Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer 2004; 91: 225-232.
21. Gasparini M, Lombardi F, Ballerini E et al. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med Pediatr Oncol 1994; 23: 406-412.
22. Hawlkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987; 56: 339-347.
23. Strauss SJ, McTieman A, Whelan JS. Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer 2004; 43: 692-697.
24. Fuchs B, Valenzuela RG, Petersen A et al, Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res 2003; (415): 82-89.
25. Li FP, Wers MH, Heise HW, Jaffe N. The course of five-year survivors of cancer in childhood. J Pediatr 1978; 93: 185-187.
26. Hayes FA, Thompson El, Parvey L et al. Metastatic Ewing's sarcoma: remission induction and survival. J Clin Oncol 1987; 5: 1199-1204.